Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase
Neil R. Aggarwal, Laurel Beaty, Tellen D. Bennett, et al.
International Journal of Infectious Diseases (2022) Vol. 128, pp. 310-317
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study
Neil Krishan Aggarwal, Kyle C. Molina, Laurel Beaty, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 6, pp. 696-705
Open Access | Times Cited: 103
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA
Mindy M. Cheng, Carolina Reyes, Sacha Satram, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 2, pp. 607-621
Open Access | Times Cited: 44
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
Daniele Focosi, Arturo Casadevall, Massimo Franchini, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 217-217
Open Access | Times Cited: 19
Efficacy and safety of sotrovimab in patients with COVID‐19: A rapid review and meta‐analysis
Bahman Amani, Behnam Amani
Reviews in Medical Virology (2022) Vol. 32, Iss. 6
Open Access | Times Cited: 30
Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations
Juthaporn Cowan, Ashley Amson, Anna Christofides, et al.
International Journal of Infectious Diseases (2023) Vol. 134, pp. 228-238
Open Access | Times Cited: 16
Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records
Christopher F. Bell, Daniel C. Gibbons, Myriam Drysdale, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0304822-e0304822
Open Access | Times Cited: 4
Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5
Kyle C. Molina, Victoria Kennerley, Laurel Beaty, et al.
International Journal of Infectious Diseases (2023) Vol. 132, pp. 34-39
Open Access | Times Cited: 8
Effectiveness of Sotrovimab and Molnupiravir in community settings in England across the Omicron BA.1 and BA.2 sublineages: emulated target trials using the OpenSAFELY platform
John Tazare, Linda Nab, Bang Zheng, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 8
Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the American College of Physicians (Version 2)
Isolde Sommer, Dominic Ledinger, Kylie Thaler, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 10, pp. 1377-1385
Open Access | Times Cited: 8
Experience with sotrovimab treatment of SARS‐CoV‐2‐infected patients in Denmark
Line Dahlerup Rasmussen, Anne‐Mette Lebech, Anne Øvrehus, et al.
British Journal of Clinical Pharmacology (2022) Vol. 89, Iss. 6, pp. 1820-1833
Open Access | Times Cited: 11
Evaluating the efficacy of different volume resuscitation strategies in acute pancreatitis patients: a systematic review and meta-analysis
Roopa Kumari, FNU Sadarat, Sindhu Luhana, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
Scott Dryden‐Peterson, Andy Kim, Mary-Ruth M Joyce, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 11
Open Access | Times Cited: 9
Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2)
Amir Qaseem, Jennifer Yost, George M. Abraham, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 10, pp. 1396-1404
Open Access | Times Cited: 5
A retrospective real-world study of early short-course remdesivir in non-hospitalized COVID-19 patients at high risk for progression: low rate of hospitalization or death, regardless of immunocompetence status
José Manuel Ramos, Héctor Pinargote‐Celorio, Jara Llenas‐García, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 5
Effectiveness of Sotrovimab in Preventing COVID-19-Related Hospitalizations or Deaths Among US Veterans During Omicron BA.1
Yinong Young‐Xu, Caroline Korves, Gabrielle Zwain, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 12
Open Access | Times Cited: 5
Unmasking the enigma: An in-depth analysis of COVID-19 impact on the pediatric population
Iman Saad Ahmed, Sara Luay Tapponi, Marwa Eltahir Widatallah, et al.
Journal of Infection and Public Health (2023) Vol. 16, Iss. 9, pp. 1346-1360
Open Access | Times Cited: 4
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C)
Christopher F. Bell, Priyanka Bobbili, Raj Desai, et al.
Clinical Drug Investigation (2024) Vol. 44, Iss. 3, pp. 183-198
Open Access | Times Cited: 1
A computational method for anti-SARS-CoV-2 antibodies neutralization power: A blueprint with monoclonal antibody Sotrovimab (Preprint)
Dana Ashoor, Maryam Marzouq, M. Dahmani Fathallah
JMIR Bioinformatics and Biotechnology (2024) Vol. 5, pp. e58018-e58018
Open Access | Times Cited: 1
In silico evaluation of anti SARS-CoV-2 antibodies neutralization power: A blueprint with monoclonal antibody Sotrovimab
Dana Ashoor, Maryam Marzouq, M. Dahmani Fathallah
Research Square (Research Square) (2023)
Open Access | Times Cited: 3
Isolation of a pair of potent broadly neutralizing mAb binding to RBD and SD1 domains of SARS-CoV-2
David I. Stuart, Chang Liu, Raksha Das, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 2
Real-world data to evaluate effects of a multi-level dissemination strategy on access, outcomes, and equity of monoclonal antibodies for COVID-19
Mika K. Hamer, Chelsea Sobczak, Lindsey Whittington, et al.
Journal of Clinical and Translational Science (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 2
A computational method for anti-SARS-CoV-2 antibodies neutralization power: A blueprint with monoclonal antibody Sotrovimab (Preprint)
Dana Ashoor, Maryam Marzouq, M. Dahmani Fathallah
(2024)
Open Access
Real-world evidence of sotrovimab effectiveness for preventing severe outcomes in patients with COVID-19: A quality improvement propensity matched retrospective cohort study of a pan-provincial program in Alberta, Canada
Gregory Farmer, Khokan C. Sikdar, TKT Lo, et al.
International Journal of Infectious Diseases (2024) Vol. 146, pp. 107136-107136
Closed Access
Rapid methods for multi-level dissemination of neutralizing monoclonal antibody treatment for COVID-19 outpatients: designing for dissemination using the fit to context framework
Bethany M. Kwan, Chelsea Sobczak, Lindsey E. Fish, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access
Comparative Effectiveness of Antivirals and Monoclonal Antibodies for Treating COVID‐19 Patients Infected With Omicron Variant: A Systematic Review and Network Meta‐Analysis
Kristy T. K. Lau, Xi Xiong, Carlos King Ho Wong, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 12
Open Access
Page 1 - Next Page

Scroll to top